IPO Preview: ContraFect (CFRX)
Seeking Alpha (registration)
Biotechnology company focused on discovering and developing therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. High price to book, 5.6. High cash burn …
ContraFect Announces Pricing of Its Initial Public OfferingMarketwired (press release)
IPO Report: ContraFect (CFRXU)Equities.com
After subscribing to the service (All Levels) this menu will become active to direct you to member database locations and weekly audio recordings. Please refresh the page if you have subscribed and are still seeing this message.